EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study

Carlotta Antoniotti iD, Daniele Rossini, Filippo Pietrantonio iD, Lisa Salvatore iD, Sara Lonardi iD, Stefano Tamberi, Federica Marmorino iD, Roberto Moretto, Michele Prisciandaro iD, Emiliano Tamburini, Giampaolo Tortora iD, Alessandro Passardi iD und 15 weitere

Journal of Clinical Oncology · 01.08.2024 · 42 (22) · 2637-2644

DOI: 10.1200/jco.23.02728 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.08.2024. Verfasst von Carlotta Antoniotti und 26 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Leucovorin, Bevacizumab. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 8 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n = 73) or FOLFOXIRI/bevacizumab plus atezolizumab (experimental group, n = 145). We present overall survival (OS) and updated outcomes according to tumor immune-related biomarkers, both in the intention-to-treat (ITT) population and the cohort of patients with proficient mismatch repair (pMMR) tumors. Median follow-up was 45.2 months (IQR, 42.6-49.2). In the ITT population, median OS was 33.0 and 27.2 months for experimental and control groups, respectively (hazard ratio [HR], 0.78 [80% CI, 0.61 to 0.98]; P = .084). An interaction effect between Immunoscore Immune-Checkpoint (IC) and treatment arm was observed ( P int , .089), with higher benefit from atezolizumab in the Immunoscore IC-high group. In the pMMR cohort (N = 202), median OS was 30.8 and 29.2 months for experimental and control groups, respectively (HR, 0.80 [80% CI, 0.63 to 1.02]; P = .117). Interactions between treatment group and tumor mutational burden (TMB) and Immunoscore IC were reported ( P int , .043 and .092, respectively), with patients bearing TMB-high and Immunoscore IC-high tumors deriving higher benefit from the addition of atezolizumab. First-line FOLFOXIRI/bevacizumab plus atezolizumab improves OS in patients with mCRC. In the pMMR group, patients with Immunoscore IC-high and/or TMB-high tumors are identified as a subgroup of interest to further develop this treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsLeucovorinBevacizumabFluorouracilAntibodies, Monoclonal, HumanizedIrinotecanHumansMaleFemaleMiddle AgedAgedOxaliplatinAdultOrganoplatinum CompoundsCamptothecin

Substanzen

atezolizumabLeucovorinBevacizumabFluorouracilAntibodies, Monoclonal, HumanizedIrinotecanOxaliplatinOrganoplatinum CompoundsCamptothecin

Autor:innen und Institutionen

  • Unit of Medical Oncology 2, University Hospital of Pisa, Pisa, Italy.
  • Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.
  • Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy.
  • Oncologia Medica, Università Cattolica del Sacro Cuore, Roma, Italy.

ORCID-Profile: Carlotta Antoniotti, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Federica Marmorino, Michele Prisciandaro, Giampaolo Tortora, Alessandro Passardi, Francesca Bergamo, Veronica Conca, Erika Martinelli, Gianluca Masi, Luca Boni, Jerome Galon, Chiara Cremolini

Zitieren

APA

Antoniotti, C., Rossini, D., Pietrantonio, F., Salvatore, L., Lonardi, S., Tamberi, S., Marmorino, F., Moretto, R., Prisciandaro, M., Tamburini, E., Tortora, G., Passardi, A., Bergamo, F., Raimondi, A., Ritorto, G., Borelli, B., Conca, V., Ugolini, C., Aprile, G., …, & Cremolini, C. (2024). Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. Journal of Clinical Oncology, 42(22), 2637-2644. https://doi.org/10.1200/jco.23.02728

Vancouver

Antoniotti C, Rossini D, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, et al. Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. Journal of Clinical Oncology. 2024;42(22):2637-2644. doi:10.1200/jco.23.02728

BibTeX
@article{Antoniotti2024,
  author = {Antoniotti, Carlotta and Rossini, Daniele and Pietrantonio, Filippo and Salvatore, Lisa and Lonardi, Sara and Tamberi, Stefano and Marmorino, Federica and Moretto, Roberto and Prisciandaro, Michele and Tamburini, Emiliano and Tortora, Giampaolo and Passardi, Alessandro and Bergamo, Francesca and Raimondi, Alessandra and Ritorto, Giuliana and Borelli, Beatrice and Conca, Veronica and Ugolini, Clara and Aprile, Giuseppe and Antonuzzo, Lorenzo and Gelsomino, Fabio and Martinelli, Erika and Pella, Nicoletta and Masi, Gianluca and Boni, Luca and Galon, Jerome and Cremolini, Chiara},
  title = {Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {22},
  pages = {2637--2644},
  doi = {10.1200/jco.23.02728}
}
Kostenlos starten →